Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004

Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbact...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of antimicrobial agents Vol. 30; no. 5; pp. 452 - 457
Main Authors Wang, Hui, Zhang, Bo, Ni, Yuxing, Kuti, Joseph L, Chen, Baiyi, Chen, Minjun, Nicolau, David P
Format Journal Article
LanguageEnglish
Published London Elsevier B.V 01.11.2007
Amsterdam Elsevier
New York, NY
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7–100%) and A. baumannii (66.0–86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9–86.6% in Southern China and 64.8–82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved ≤50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa . Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.
AbstractList Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved <=50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.
Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved < or =50% CFR against all bacterial species. Meropenem 2g every 8h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.
Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7–100%) and A. baumannii (66.0–86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9–86.6% in Southern China and 64.8–82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved ≤50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa . Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.
Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7–100%) and A. baumannii (66.0–86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9–86.6% in Southern China and 64.8–82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved ≤50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.
Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved &lt; or =50% CFR against all bacterial species. Meropenem 2g every 8h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.
Author Ni, Yuxing
Chen, Minjun
Nicolau, David P
Wang, Hui
Chen, Baiyi
Zhang, Bo
Kuti, Joseph L
Author_xml – sequence: 1
  fullname: Wang, Hui
– sequence: 2
  fullname: Zhang, Bo
– sequence: 3
  fullname: Ni, Yuxing
– sequence: 4
  fullname: Kuti, Joseph L
– sequence: 5
  fullname: Chen, Baiyi
– sequence: 6
  fullname: Chen, Minjun
– sequence: 7
  fullname: Nicolau, David P
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19163889$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17646088$$D View this record in MEDLINE/PubMed
BookMark eNqNkk-LFDEQxYOsuLOrX0HiQW895k93kr4IMqyrsKCgnkN1uno2Y3d6TTIDc_Gzm2YGVrzoqerwq1fFe3VFLsIckJBXnK054-rtbu13ELKfvIPtWjCm10ytGWuekBU3WlS65fKCrFgr6so0ur0kVyntGOONrJtn5JJrVStmzIr8-nIPcQI398cARY9miFvMFHIGHyYMmc4DTXjAQM8r49x5GBOFbSFSprcRpirgFrI_IO3AZYweqJvHEUvf0yHOE93c-wDUB1rOlUWqX5r6OXk6FC18ca7X5PuHm2-bj9Xd59tPm_d3lWsanSvsVCew5mbopXaAgxSiZZpp3hjDhwY1OGlki6IXPRs6VrdOqhpN17O-M05ekzcn3Yc4_9xjynbyyeE4QsB5n6wyshHFqH-CvFVc1rUqYHsCix8pRRzsQ_QTxKPlzC4p2Z39IyW7pGSZsiWlMvvyvGTfTdg_Tp5jKcDrMwDJwThECM6nR67lShqzXLs5cVi8O3iMNjmPwWHvY_He9rP_r3Pe_aXiRh8KNv7AI6bdvI-hhGO5TcIy-3V5q-WrSgBMaNHI3y4qzaE
CitedBy_id crossref_primary_10_1007_s10156_011_0271_9
crossref_primary_10_1155_2021_1175379
crossref_primary_10_2133_dmpk_DMPK_11_RG_027
crossref_primary_10_1038_s41598_024_60909_7
crossref_primary_10_1097_IPC_0000000000000141
crossref_primary_10_1179_1973947814Y_0000000214
crossref_primary_10_1179_1973947815Y_0000000078
crossref_primary_10_1002_phar_2505
crossref_primary_10_1128_AAC_00385_20
crossref_primary_10_1186_cc11405
crossref_primary_10_1186_cc11459
crossref_primary_10_1016_j_micpath_2019_103809
crossref_primary_10_1128_AAC_00126_11
crossref_primary_10_1186_1471_2334_10_171
crossref_primary_10_1016_j_ijantimicag_2008_08_023
crossref_primary_10_1345_aph_1P187
crossref_primary_10_1016_j_ijantimicag_2019_06_021
crossref_primary_10_1111_bcp_15819
crossref_primary_10_1007_s11096_018_0720_y
crossref_primary_10_1007_s10156_009_0001_8
crossref_primary_10_1016_j_cmi_2020_11_032
crossref_primary_10_1345_aph_1M339
crossref_primary_10_3390_antibiotics10080993
crossref_primary_10_1016_j_heliyon_2024_e32600
Cites_doi 10.1086/516284
10.1097/01.inf.0000094940.81959.14
10.1016/j.ijantimicag.2006.07.014
10.1016/j.diagmicrobio.2005.04.004
10.1086/510590
10.1016/j.diagmicrobio.2005.10.004
10.1016/j.diagmicrobio.2004.09.001
10.1128/AAC.45.1.13-22.2001
10.1592/phco.27.3.333
ContentType Journal Article
Copyright Elsevier B.V. and the International Society of Chemotherapy
2007 Elsevier B.V. and the International Society of Chemotherapy
2007 INIST-CNRS
Copyright_xml – notice: Elsevier B.V. and the International Society of Chemotherapy
– notice: 2007 Elsevier B.V. and the International Society of Chemotherapy
– notice: 2007 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7T7
8FD
C1K
FR3
P64
7X8
DOI 10.1016/j.ijantimicag.2007.06.005
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Engineering Research Database
Technology Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Bacteriology Abstracts (Microbiology B)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Engineering Research Database
MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1872-7913
EndPage 457
ExternalDocumentID 10_1016_j_ijantimicag_2007_06_005
17646088
19163889
S0924857907002725
1_s2_0_S0924857907002725
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Asia
China
GeographicLocations_xml – name: China
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29J
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AAAJQ
AABNK
AACTN
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXKI
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABXDB
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADVLN
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGEKW
AGHFR
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CJTIS
CNWQP
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEJ
HMG
HMK
HMO
HVGLF
HX~
HZ~
IHE
J1W
KOM
LUGTX
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OD-
OO.
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SIN
SPCBC
SSH
SSI
SSZ
T5K
UNMZH
WUQ
XPP
Z5R
~G-
AAIAV
ABLVK
ABYKQ
AJBFU
EFLBG
LCYCR
ABPIF
ABPTK
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7T7
8FD
C1K
FR3
P64
7X8
ID FETCH-LOGICAL-c557t-eb6b2e418fd37caef3229070715881f5e7ac3839e2d2d0fb049c364e8bd0db8c3
IEDL.DBID .~1
ISSN 0924-8579
IngestDate Thu Oct 24 23:45:38 EDT 2024
Sat Oct 26 00:53:17 EDT 2024
Thu Sep 26 19:04:53 EDT 2024
Sat Sep 28 07:43:37 EDT 2024
Sun Oct 22 16:04:13 EDT 2023
Fri Feb 23 02:34:42 EST 2024
Tue Oct 15 22:55:10 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Antibiotic
Pharmacodynamics
Bacterial resistance
Infection
Resistance
Target
Targeting
Bacteriosis
Antibacterial agent
Biological activity
Antimicrobial agent
Gram negative bacteria
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c557t-eb6b2e418fd37caef3229070715881f5e7ac3839e2d2d0fb049c364e8bd0db8c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17646088
PQID 19613446
PQPubID 23462
PageCount 6
ParticipantIDs proquest_miscellaneous_68352579
proquest_miscellaneous_19613446
crossref_primary_10_1016_j_ijantimicag_2007_06_005
pubmed_primary_17646088
pascalfrancis_primary_19163889
elsevier_sciencedirect_doi_10_1016_j_ijantimicag_2007_06_005
elsevier_clinicalkeyesjournals_1_s2_0_S0924857907002725
PublicationCentury 2000
PublicationDate 2007-11-01
PublicationDateYYYYMMDD 2007-11-01
PublicationDate_xml – month: 11
  year: 2007
  text: 2007-11-01
  day: 01
PublicationDecade 2000
PublicationPlace London
Amsterdam
New York, NY
PublicationPlace_xml – name: Amsterdam
– name: London
– name: New York, NY
– name: Netherlands
PublicationTitle International journal of antimicrobial agents
PublicationTitleAlternate Int J Antimicrob Agents
PublicationYear 2007
Publisher Elsevier B.V
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Elsevier
References Zhang, Wang, Jiang (bib10) 2000; 9
Craig (bib3) 1998; 26
Wang, Peng, Xiao (bib8) 2001; 6
Wang, Chen (bib1) 2005; 51
Ludwig, Konkoly-Thege, Kuti (bib14) 2006; 28
Kuti, Nicolau (bib5) 2005; 53
Zong, Xiao, Zhang (bib9) 1994; 10
Zhang, Wang, Zhang (bib11) 1995; 13
DeRyke, Kuti, Nicolau (bib6) 2007; 27
Bradley, Dudley, Drusano (bib4) 2003; 22
Hirakata, Matsuda, Miyazaki (bib2) 2005; 52
Drusano, Preston, Hardalo (bib13) 2001; 45
Tan, Sun, Yang (bib12) 1995; 6
Lodise, Lomaestro, Drusano (bib15) 2007; 44
Zhao, Li, Zhang (bib7) 2004; 20
Zhang (10.1016/j.ijantimicag.2007.06.005_bib10) 2000; 9
Tan (10.1016/j.ijantimicag.2007.06.005_bib12) 1995; 6
Zhao (10.1016/j.ijantimicag.2007.06.005_bib7) 2004; 20
Ludwig (10.1016/j.ijantimicag.2007.06.005_bib14) 2006; 28
Zhang (10.1016/j.ijantimicag.2007.06.005_bib11) 1995; 13
Hirakata (10.1016/j.ijantimicag.2007.06.005_bib2) 2005; 52
Lodise (10.1016/j.ijantimicag.2007.06.005_bib15) 2007; 44
DeRyke (10.1016/j.ijantimicag.2007.06.005_bib6) 2007; 27
Drusano (10.1016/j.ijantimicag.2007.06.005_bib13) 2001; 45
Kuti (10.1016/j.ijantimicag.2007.06.005_bib5) 2005; 53
Bradley (10.1016/j.ijantimicag.2007.06.005_bib4) 2003; 22
Wang (10.1016/j.ijantimicag.2007.06.005_bib8) 2001; 6
Zong (10.1016/j.ijantimicag.2007.06.005_bib9) 1994; 10
Craig (10.1016/j.ijantimicag.2007.06.005_bib3) 1998; 26
Wang (10.1016/j.ijantimicag.2007.06.005_bib1) 2005; 51
References_xml – volume: 51
  start-page: 201
  year: 2005
  end-page: 208
  ident: bib1
  article-title: Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002
  publication-title: Diagn Microbiol Infect Dis
  contributor:
    fullname: Chen
– volume: 26
  start-page: 1
  year: 1998
  end-page: 12
  ident: bib3
  article-title: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
  publication-title: Clin Infect Dis
  contributor:
    fullname: Craig
– volume: 20
  start-page: 161
  year: 2004
  end-page: 164
  ident: bib7
  article-title: Pharmacokinetics of meropenem single dose intravenous in healthy volunteers
  publication-title: Chin J Clin Pharmacol
  contributor:
    fullname: Zhang
– volume: 6
  start-page: 25
  year: 1995
  end-page: 26
  ident: bib12
  article-title: Comparison of pharmacokinetics of domestic and imported ciprofloxacin injection in healthy volunteers
  publication-title: Zhongguo Yaofang
  contributor:
    fullname: Yang
– volume: 27
  start-page: 333
  year: 2007
  end-page: 342
  ident: bib6
  article-title: Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against
  publication-title: Pharmacotherapy
  contributor:
    fullname: Nicolau
– volume: 9
  start-page: 75
  year: 2000
  end-page: 78
  ident: bib10
  article-title: Pharmacokinetics of intravenously administered cefoperazone/sulbactam in normal volunteers
  publication-title: Chin J Clin Pharm
  contributor:
    fullname: Jiang
– volume: 45
  start-page: 13
  year: 2001
  end-page: 22
  ident: bib13
  article-title: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Hardalo
– volume: 52
  start-page: 323
  year: 2005
  end-page: 329
  ident: bib2
  article-title: Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia–Pacific region (SENTRY 1998–2002)
  publication-title: Diagn Microbiol Infect Dis
  contributor:
    fullname: Miyazaki
– volume: 10
  start-page: 385
  year: 1994
  end-page: 388
  ident: bib9
  article-title: The pharmacokinetics of ceftazidime in burned patients
  publication-title: Zhonghua Zhengxing Shangshao Waike Zazhi
  contributor:
    fullname: Zhang
– volume: 13
  start-page: 195
  year: 1995
  end-page: 198
  ident: bib11
  article-title: Clinical pharmacokinetic study on cephalosporins and the proposed therapeutic regimens
  publication-title: Zhongguo Chuanranbing Zazhi
  contributor:
    fullname: Zhang
– volume: 28
  start-page: 433
  year: 2006
  end-page: 438
  ident: bib14
  article-title: Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against
  publication-title: Int J Antimicrob Agents
  contributor:
    fullname: Kuti
– volume: 44
  start-page: 357
  year: 2007
  end-page: 363
  ident: bib15
  article-title: Piperacillin–tazobactam for
  publication-title: Clin Infect Dis
  contributor:
    fullname: Drusano
– volume: 53
  start-page: 281
  year: 2005
  end-page: 287
  ident: bib5
  article-title: Making the most of surveillance studies: summary of the OPTAMA Program
  publication-title: Diagn Microbiol Infect Dis
  contributor:
    fullname: Nicolau
– volume: 6
  start-page: 391
  year: 2001
  end-page: 393
  ident: bib8
  article-title: Pharmacokinetics of imipenem in burned patients
  publication-title: Xinan Guofang Yiyao
  contributor:
    fullname: Xiao
– volume: 22
  start-page: 982
  year: 2003
  end-page: 992
  ident: bib4
  article-title: Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation
  publication-title: Pediatr Infect Dis J
  contributor:
    fullname: Drusano
– volume: 26
  start-page: 1
  year: 1998
  ident: 10.1016/j.ijantimicag.2007.06.005_bib3
  article-title: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
  publication-title: Clin Infect Dis
  doi: 10.1086/516284
  contributor:
    fullname: Craig
– volume: 6
  start-page: 391
  year: 2001
  ident: 10.1016/j.ijantimicag.2007.06.005_bib8
  article-title: Pharmacokinetics of imipenem in burned patients
  publication-title: Xinan Guofang Yiyao
  contributor:
    fullname: Wang
– volume: 20
  start-page: 161
  year: 2004
  ident: 10.1016/j.ijantimicag.2007.06.005_bib7
  article-title: Pharmacokinetics of meropenem single dose intravenous in healthy volunteers
  publication-title: Chin J Clin Pharmacol
  contributor:
    fullname: Zhao
– volume: 22
  start-page: 982
  year: 2003
  ident: 10.1016/j.ijantimicag.2007.06.005_bib4
  article-title: Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/01.inf.0000094940.81959.14
  contributor:
    fullname: Bradley
– volume: 6
  start-page: 25
  year: 1995
  ident: 10.1016/j.ijantimicag.2007.06.005_bib12
  article-title: Comparison of pharmacokinetics of domestic and imported ciprofloxacin injection in healthy volunteers
  publication-title: Zhongguo Yaofang
  contributor:
    fullname: Tan
– volume: 28
  start-page: 433
  year: 2006
  ident: 10.1016/j.ijantimicag.2007.06.005_bib14
  article-title: Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2006.07.014
  contributor:
    fullname: Ludwig
– volume: 13
  start-page: 195
  year: 1995
  ident: 10.1016/j.ijantimicag.2007.06.005_bib11
  article-title: Clinical pharmacokinetic study on cephalosporins and the proposed therapeutic regimens
  publication-title: Zhongguo Chuanranbing Zazhi
  contributor:
    fullname: Zhang
– volume: 52
  start-page: 323
  year: 2005
  ident: 10.1016/j.ijantimicag.2007.06.005_bib2
  article-title: Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia–Pacific region (SENTRY 1998–2002)
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2005.04.004
  contributor:
    fullname: Hirakata
– volume: 10
  start-page: 385
  year: 1994
  ident: 10.1016/j.ijantimicag.2007.06.005_bib9
  article-title: The pharmacokinetics of ceftazidime in burned patients
  publication-title: Zhonghua Zhengxing Shangshao Waike Zazhi
  contributor:
    fullname: Zong
– volume: 44
  start-page: 357
  year: 2007
  ident: 10.1016/j.ijantimicag.2007.06.005_bib15
  article-title: Piperacillin–tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy
  publication-title: Clin Infect Dis
  doi: 10.1086/510590
  contributor:
    fullname: Lodise
– volume: 53
  start-page: 281
  year: 2005
  ident: 10.1016/j.ijantimicag.2007.06.005_bib5
  article-title: Making the most of surveillance studies: summary of the OPTAMA Program
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2005.10.004
  contributor:
    fullname: Kuti
– volume: 51
  start-page: 201
  year: 2005
  ident: 10.1016/j.ijantimicag.2007.06.005_bib1
  article-title: Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2004.09.001
  contributor:
    fullname: Wang
– volume: 9
  start-page: 75
  year: 2000
  ident: 10.1016/j.ijantimicag.2007.06.005_bib10
  article-title: Pharmacokinetics of intravenously administered cefoperazone/sulbactam in normal volunteers
  publication-title: Chin J Clin Pharm
  contributor:
    fullname: Zhang
– volume: 45
  start-page: 13
  year: 2001
  ident: 10.1016/j.ijantimicag.2007.06.005_bib13
  article-title: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.45.1.13-22.2001
  contributor:
    fullname: Drusano
– volume: 27
  start-page: 333
  year: 2007
  ident: 10.1016/j.ijantimicag.2007.06.005_bib6
  article-title: Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.27.3.333
  contributor:
    fullname: DeRyke
SSID ssj0015345
Score 2.0624912
Snippet Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese...
Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals,...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 452
SubjectTerms Acinetobacter baumannii
Anti-Bacterial Agents - pharmacokinetics
Antibiotic
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial resistance
Biological and medical sciences
China
Computer Simulation
Enterobacteriaceae
Enterobacteriaceae - drug effects
Enterobacteriaceae Infections - drug therapy
Enterobacteriaceae Infections - microbiology
Escherichia coli
Humans
Infectious Disease
Klebsiella pneumoniae
Medical sciences
Microbial Sensitivity Tests
Monte Carlo Method
Pharmacodynamics
Pharmacology. Drug treatments
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Pseudomonas Infections - drug therapy
Pseudomonas Infections - microbiology
Title Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0924857907002725
https://dx.doi.org/10.1016/j.ijantimicag.2007.06.005
https://www.ncbi.nlm.nih.gov/pubmed/17646088
https://search.proquest.com/docview/19613446
https://search.proquest.com/docview/68352579
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYhpaVQSpu-tm22Uyg5xV0_ZMuGXkJoum0hBJpAbkKy5MWBepfYOewlv70zkh0nhIVAb-tFlsfSSDNjffMNY18SGykThcRTaaqAq8IGik7ZU4U-UlIKIgUjtMVxNj_jv87T8y12OOTCEKyy3_v9nu526_6fWT-as1Vdz_6EBdFxCYzuKLaKKdGco_lDnf56fQPzwAXtChVT44BaP2GfR4xXfYHi15SXv-jZDOloIt1ko56tVIsjV_mSF5t9Umebjl6w571TCQde7pdsyzY77LEvM7neYXsnnp96vQ-nY7pVuw97cDIyV69fsevh0vg69eBx4qC6ATYAywpaIn2C_pWIxgk1GNQCW7Qd_LhUf4PGLhyfOGjPBa2A1A2H2RqgfBZwVbuhboBAa9iVoR_8NTs7-n56OA_6Ag1BmaaiC6zOdGx5lFcmEaWyVULs8QK9ljTPoyq1QpUYARc2NrEJK43RSJlk3ObahEbnZfKGbTfLxr5jgNe6MDypMCLneaxz7ARjRSOUCgsTpRMWD1MiV56HQw4AtQt5ax6prqaQDqyHN4lh8uSQaIpbo237ddrKSLaxDOU9XZqwbzd33lFHiZbmIQ-e3lGVUeSC_N-8mLBPg-5IXM90SKMau7xCiQp0sDBG39wiyx2FLfbx1ivd2LvIeIZm4_3_Sf-BPXVfsF3G5Ue23V1e2V10vTo9dWtryh4d_Pw9P_4He5Qvgw
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7ShLaBUto0bbaPRIWSU8z6JcuCXkJoumnSJdAN5CZkS14cqHeJncNe-ts7Y9lxQ1ko9GYZaazHjDRjzXwD8CmygTaBTziVpvBiLa2n6Zada9SRolwQKBh5W0yTyVX87Zpfb8BJHwtDbpXd3u_29Ha37t6Mu9kcL8ty_MOXBMcl0Loj2yrkj2ALtQGJ0rl1fHY-md5fJvCozVVM9T1q8AQ-Dm5e5Q2OoKTQ_HkHaEi3E3zdMfVsqWucvMJlvVivlrbH0-kLeN7plezYdf0lbNhqBx67TJOrHTi8dBDVqyM2GyKu6iN2yC4H8OrVK_jVF41LVc-cqzjTTe85wBYFqwn3iXVDIiQnZGKm51ijbtjXW_3Tq-y8hRRnmYOD1ow4DmfaGkYhLaxN3M3KipHfGpIy9BDvwtXpl9nJxOtyNHg556LxbJZkoY2DtDCRyLUtIgKQF6i48DQNCm6FztEIljY0ofGLDA2SPEpim2bGN1maR69hs1pUdg8YljNp4qhAozxOwyxFImguGqG1L03ARxD2S6KWDopD9T5qN-qPdaTUmkK1_nrYSPSLp_pYU9wdbd2Jaq0CVYfKV3-x0wg-37d8wJEKD5t_-fD-A1YZuixJBU7lCA563lEo0nRPoyu7uMMeSdSx0ExfXyNJWxRbpPHGMd1AXSRxgifH2__r_QE8ncy-X6iLs-n5O9huf2i3AZjvYbO5vbMfUBNrsv1O0n4DzLYyNw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacodynamic+target+attainment+of+seven+antimicrobials+against+Gram-negative+bacteria+collected+from+China+in+2003+and+2004&rft.jtitle=International+journal+of+antimicrobial+agents&rft.au=Wang%2C+Hui&rft.au=Zhang%2C+Bo&rft.au=Ni%2C+Yuxing&rft.au=Kuti%2C+Joseph+L&rft.date=2007-11-01&rft.issn=0924-8579&rft.volume=30&rft.issue=5&rft.spage=452&rft.epage=457&rft_id=info:doi/10.1016%2Fj.ijantimicag.2007.06.005&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09248579%2FS0924857907X01729%2Fcov150h.gif